Equities researchers at Maxim Group assumed coverage on shares of TuHURA Biosciences (NASDAQ:HURA – Get Free Report) in a report issued on Tuesday, Briefing.com reports. The firm set a “buy” rating and a $15.00 price target on the stock.
TuHURA Biosciences Price Performance
TuHURA Biosciences Company Profile
TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Further Reading
- Five stocks we like better than TuHURA Biosciences
- Using the MarketBeat Dividend Yield Calculator
- Why Warren Buffett’s 1999 Market Warning Still Matters Today
- High Flyers: 3 Natural Gas Stocks for March 2022
- Medicare Advantage Costs Surge: How These 2 Insurers Are Thriving
- Following Congress Stock Trades
- Mobileye’s Recovery Steadily Gains Traction with Novel AI
Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
